Sunshine Biopharma (SBFM) Capital Expenditures (2015 - 2026)
Sunshine Biopharma (SBFM) posted Capital Expenditures of $5129.0 for Q1 2026, up 593.65% on a QoQ basis from -$1039.0 in Q4 2025, and down 31.52% year-over-year from $7490.0 in Q1 2025.
Sunshine Biopharma (SBFM) Capital Expenditures (2015 - 2026) Analysis & Trends
Sunshine Biopharma's Capital Expenditures history runs 11 years deep, the most recent figure standing at $5129.0 for Q1 2026.
- Quarterly Capital Expenditures fell 31.52% year-over-year to $5129.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172130.0 (down 89.25% YoY) and the FY2025 annual result came in at $174491.0, down 89.47% from the prior year.
- Capital Expenditures was $5129.0 for Q1 2026 at Sunshine Biopharma, up from -$1039.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $974513.0 in Q2 2024 and bottomed at -$382363.0 in Q4 2023.
- A 5-year average of $138160.7 and a median of $36285.5 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 297.11% — and 2024, when it soared 5266.46%.
- Sunshine Biopharma's Capital Expenditures stood at $193982.0 in 2022, then sank by 297.11% to -$382363.0 in 2023, then soared by 126.83% to $102600.0 in 2024, then sank by 101.01% to -$1039.0 in 2025, then soared by 593.65% to $5129.0 in 2026.
- Business Quant data shows SBFM's Capital Expenditures at $5129.0 in Q1 2026, -$1039.0 in Q4 2025, and $8040.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 99.60 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 5,129.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,129.00 |
| Mar 31, 2026 | 5,129.00 |
| Dec 31, 2025 | -1,039.00 |
| Dec 31, 2025 | -1,039.00 |
| Sep 30, 2025 | 8,040.00 |
| Sep 30, 2025 | 8,040.00 |
| Jun 30, 2025 | 160,000.00 |
| Jun 30, 2025 | 160,000.00 |
| Mar 31, 2025 | 7,490.00 |
| Mar 31, 2025 | 7,490.00 |
| Dec 31, 2024 | 102,600.00 |
| Dec 31, 2024 | 102,600.00 |
| Sep 30, 2024 | 517,005.00 |
| Sep 30, 2024 | 517,005.00 |
| Jun 30, 2024 | 974,513.00 |
| Jun 30, 2024 | 974,513.00 |
| Mar 31, 2024 | 62,937.00 |
| Mar 31, 2024 | 62,937.00 |
| Dec 31, 2023 | -382,363.00 |
| Dec 31, 2023 | -382,363.00 |